Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

August 23, 2023

Primary Completion Date

January 21, 2025

Study Completion Date

April 8, 2025

Conditions
Diabetic Macular EdemaRetinal DiseaseMacular EdemaDiabetes MellitusDiabetic RetinopathyRetinal DegenerationRetinal DiseasesEye DiseasesEdema
Interventions
DRUG

Aflibercept

Anti-VEGF control

DRUG

foselutoclax

Experimental drug

Trial Locations (19)

16507

Erie Retina Research, LLC, Erie

19141

Vision Research Solutions, PLLC, Philadelphia

21740

Cumberland Valley Retina Consultants, Hagerstown

29605

Retina Consultants of Carolina, Greenville

32901

Florida Eye Associates, Melbourne

33064

Rand Eye Institute, Deerfield Beach

33711

Retina Vitreous Associates of Florida, St. Petersburg

46290

Midwest Eye, Carmel

60439

University Retina and Macula Associates, Lemont

76092

Retina Center of Texas, Southlake

78681

Austin Retina Associates, Round Rock

79606

Retina Research Institution of Texas, Abilene

80503

Advanced Vision Research Institute, Longmont

89502

Sierra Eye Associates, Reno

90211

Retina-Vitreous Associates Medical Group, Beverly Hills

92647

Salehi Retina Institute Inc., Huntington Beach

93309

California Retina Consultants, Bakersfield

94598

Bay Area Retina Associates, Walnut Creek

97225

EyeHealth Northwest, Portland

All Listed Sponsors
lead

Unity Biotechnology, Inc.

INDUSTRY

NCT06011798 - Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE) | Biotech Hunter | Biotech Hunter